Rojas-Gimenez, MartaLopez-Medina, ClementinaCalvo-Gutierrez, JerusalemPuche-Larrubia, Maria AngelesGomez-Garcia, IgnacioSegui-Azpilcueta, PedroAbalos-Aguilera, Maria Del CarmenRuiz, DesireeCollantes-Estevez, EduardoEscudero-Contreras, Alejandro2023-05-032023-05-032021-12-27Rojas-Giménez M, López-Medina C, Calvo-Gutiérrez J, Puche-Larrubia MÁ, Gómez-García I, Seguí-Azpilcueta P, et al. Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis. Diagnostics (Basel). 2021 Dec 28;12(1):642075-4418http://hdl.handle.net/10668/20956The objective of this study was to assess the association of carotid intima-media thickness (CIMT), and also the presence of atheromatous plaque, with biological and targeted synthetic disease-modifying antirheumatic drugs, in an established cohort of patients with rheumatoid arthritis (RA). We conducted a cross-sectional observational study based on a cohort of patients with RA and a registry of healthy controls, in whom the CIMT and presence of atheromatous plaque were assessed by ultrasound. Data were collected on disease activity, lab results and treatments. Descriptive and bivariate analyses were performed and two multivariate linear regression models (with CIMT as the dependent variable) were constructed to identify variables independently associated with CIMT in our sample of patients with RA. A total of 176 individuals (146 patients with RA and 30 controls) were included. A higher percentage of patients than controls had atheromatous plaque (33.8% vs. 12.5%, p = 0.036), but no differences were found in terms of CIMT (0.64 vs. 0.61, p = 0.444). Compared to values in patients on other therapies, the CIMT was smaller among patients on tumour necrosis factor alpha (TNFα) inhibitors (mean [SD]: 0.58 [0.10] vs. 0.65 [0.19]; p = 0.013) and among those on Janus kinase inhibitors (mean [SD]: 0.52 [0.02] vs. 0.64 [0.18]; p The use of TNFα inhibitors may protect against subclinical atherosclerosis in patients with RA, patients on this biologic having smaller CIMTs than patients on other disease-modifying antirheumatic drugs. Nonetheless, these results should be confirmed in prospective studies with larger sample sizes.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Biological therapyCardiovascular riskRheumatoid arthritisSubclinical atherosclerosisPlaque, atheroscleroticCarotid intima-media thicknessProspective studiesTumor necrosis factor inhibitorsAntirheumatic agentsLinear modelsAtherosclerosisArthritis, rheumaticresearch article35054229open accessAntirreumáticosAterosclerosisEstudios prospectivosFiebre reumáticaGrosor intima-media carotídeoInhibidores del factor de necrosis tumoralModelos LinealesPlaca aterosclerótica10.3390/diagnostics12010064PMC8775122https://www.mdpi.com/2075-4418/12/1/64/pdf?version=1640780713https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775122/pdf